Vincent Brichard
Vorstandsvorsitzender bei Egle Therapeutics SAS
Ursprung des Netzwerks ersten Grades von Vincent Brichard
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.
30
| Subsidiary | Investment Managers | 30 |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands.
22
| Subsidiary | Investment Managers | 22 |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.
15
| Holding Company | Biotechnology | 15 |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Nouscom Srl
10
| Subsidiary | Miscellaneous Commercial Services | 10 |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.
8
| Holding Company | Pharmaceuticals: Major | 8 |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.
7
| Holding Company | Biotechnology | 7 |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Vincent Brichard
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Founder Chief Executive Officer | |
| University of Utrecht | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin Masters Business Admin | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| Erasmus University Rotterdam | College/University | Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| Vrije Universiteit Amsterdam | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Analyst Private Equity Analyst Private Equity Analyst Private Equity Analyst | |
| Radboud University Nijmegen | College/University | Undergraduate Degree Graduate Degree General Counsel | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Doctorate Degree | |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| KUROS BIOSCIENCES AG | Biotechnology | Director/Board Member Director/Board Member Chairman | |
LSP Advisory BV
 LSP Advisory BV Investment ManagersFinance Part of LSP Advisory Group BV, EQT Life Sciences is a healthcare investment firm based in Amsterdam, Netherlands. EQT Life Sciences has been connecting investors to inventors in the healthcare sector for over 30 years. The Dutch company has invested in close to two hundred private companies, raising billions of additional capital directed at supporting their R & D. EQT Life Sciences believes in fostering life and constant innovation in healthcare to achieve that goal. The company was founded in 1998, and Mark A. Wegter has been the CEO since then. Recently, EQT Life Sciences was acquired by EQT AB, one of the largest private equity firms in Europe, and among the top-ten private equity firms globally. | Investment Managers | Director/Board Member Chief Executive Officer Director/Board Member | |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Participatiemaatschappij Vlaanderen NV
 Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
ViCentra BV
 ViCentra BV Electronic Equipment/InstrumentsElectronic Technology ViCentra BV engages in the development of medical devices. It focuses in creating devices for diabetes patients. The company was founded by Tim Oakes and Joseph John Cefai in 2013 and is headquartered in Utrecht, the Netherlands. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member Director/Board Member | |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
| CELYAD ONCOLOGY SA | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| POXEL | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Morphochem AG
 Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Private Equity Investor Private Equity Investor | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Gimv (Private Equity)
 Gimv (Private Equity) Investment ManagersFinance Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium. | Investment Managers | Director/Board Member Private Equity Investor | |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IMMUNIC, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| BIOM'UP | Medical Specialties | Director/Board Member Director/Board Member | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| Université Libre de Bruxelles | College/University | Doctorate Degree Undergraduate Degree | |
MaSTherCell SA
 MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | Biotechnology | Director/Board Member Chief Executive Officer | |
| OCULIS HOLDING AG | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
EyeSense AG
 EyeSense AG Medical SpecialtiesHealth Technology EyeSense AG develops novel continuous blood glucose monitoring systems for diabetes patients. The firm's continuous glucose monitoring (CGM) gives a sense of security to diabetic patients. The company was founded by Achim Müller in 2006 and is headquartered in Basel, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member | |
iSTAR Medical SA
 iSTAR Medical SA Medical SpecialtiesHealth Technology iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium. | Medical Specialties | Director/Board Member Director/Board Member | |
STAT-Dx Life SL
 STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member Director/Board Member |
Statistik
International
| Niederlande | 15 |
| Belgien | 13 |
| Schweiz | 8 |
| Vereinigte Staaten | 6 |
| Frankreich | 5 |
Sektoral
| Health Technology | 34 |
| Consumer Services | 8 |
| Finance | 7 |
| Commercial Services | 4 |
| Electronic Technology | 2 |
Operativ
| Director/Board Member | 608 |
| Corporate Officer/Principal | 110 |
| Chairman | 89 |
| Private Equity Investor | 79 |
| Independent Dir/Board Member | 70 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Pierre Legault | 45 |
| Raphaël Wisniewski | 45 |
| Göran Albert Ando | 44 |
| Stefan Yee | 39 |
| Marijn Dekkers | 35 |
| Jörg Neermann | 34 |
| Regina Hodits | 34 |
| Martijn Kleijwegt | 33 |
| Scott Rocklage | 32 |
| Jean-Paul Prieels | 32 |
| René Kuijten | 30 |
| Rémi Droller | 29 |
| Rudy Dekeyser | 29 |
| Florent Gros | 28 |
| Colin Goddard | 26 |
- Börse
- Insiders
- Vincent Brichard
- Unternehmensverbindungen